Research updates · checked November 7, 2026
What changed, and when.
New trials, publications and regulatory decisions for the compounds in our library, newest first. Every entry links to its source.
November 2026
Psoriatic arthritis data at ACR
Lilly presents TOGETHER-PsA, a phase 3b study of ixekizumab with tirzepatide in psoriatic arthritis with obesity.
Read the sourceTRIUMPH-4 at ACR Convergence
Lilly presents the 68-week phase 3 TRIUMPH-4 trial in knee osteoarthritis pain as a plenary; knee data from TRIUMPH-1 follow on November 10.
Read the source
October 2026
First head-to-head phase 3
Sponsor-reported TRANSCEND-T2D-2 results compare retatrutide with semaglutide 2 mg in type 2 diabetes over 80 weeks. Full results are not yet published.
Read the sourceHHS interim compounding policy
HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.
Read the sourceOrthopaedic review
A JAAOS review of BPC-157, thymosin beta-4 and TB-500 finds mostly preclinical evidence.
Read the sourceExpert caution on clinical claims
A commentary in Aesthetic Surgery Journal warns that mechanistic plausibility is not clinical validation.
Read the source
September 2026
TRIUMPH-1 and TRIUMPH-2 published
TRIUMPH-1 appeared in NEJM and TRIUMPH-2 in The Lancet.
Read the source
July 2026
FDA advisory committee votes
FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).
Read the sourceTRIUMPH-2 and TRIUMPH-3 topline
Lilly reported topline results and said it plans to submit to FDA in Q1 2027.
Read the source
April 2026
Category 2 removals
FDA announced the removal of 12 peptide substances from its Category 2 compounding list, effective about April 22, 2026. Removal is not approval.
Read the source
February 2026
January 2026
Precursors compared head to head
A randomized study in 65 adults found NR and NMN raised blood NAD+ over 14 days while nicotinamide did not.
Read the source